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of intergenerational discounting. CONCLUSIONS: Cost-
effectiveness analysis will increasingly play an informative role in
policy analysis of public health interventions even though it is not
clear what discount rate is appropriate in each case. However,
especially for programmes characterized by long-term dimin-
ished risk of disease, death or sequel avoided, possibility of
disease eradication, and substantial intergenerational impact,
there are no convincing arguments favouring the use of subjective
time preferences when setting ofﬁcial discount rates for applica-
tion in social project evaluation.
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OBJECTIVES: In cost-effectiveness analysis, we aim to account
for all future costs and beneﬁts for all patients who are currently
eligible for a new health technology and who will become eligible
in the future. METHODS: We adapt the fundamental concept
from epidemiology of the incidence and prevalence of a disease to
cost-effectiveness analysis. We deﬁne the prevalent cohort as
those patients eligible to switch from the comparator to the new
technology at the time the new technology is introduced. Next,
we introduce the concept of multiple future incident cohorts. The
incident cohort starting t years in the future consists of those
patients who ﬁrst become eligible for the new technology t years
in the future. Currently cost-effectiveness analyses worldwide
consider only either the prevalent cohort, the incident cohort in
only the ﬁrst year, or a mixture of the two. RESULTS: On
average, patients in the prevalent cohort are older and at a more
advanced stage of illness than patients in the incident cohort. If
the cost and beneﬁt discount rates differ, we show mathemati-
cally that the cost-effectiveness of all technologies will be sub-
stantially affected by our method. Otherwise, the incremental
cost-effectiveness ratio will not change for acute conditions, but
may change substantially for chronic conditions, particularly for
chronic progressive conditions. CONCLUSIONS: We suggest
that analyses capture the costs and beneﬁts arising from the
prevalent cohort and all future incident cohorts. If our method
had been used in the past, some health technologies would have
appeared substantially more cost-effective, others substantially
less cost-effective. If possible, parameter values (e.g. average age,
disease severity) for both the incident and prevalent cohorts
should be obtained from the literature. Otherwise, we describe
how such parameters can be estimated.
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OBJECTIVES: Economic evaluation(EE) incorporate some
degree of uncertainty and variability that arises in a number of
ways. Uncertainty represents lack of perfect knowledge on the
part of the analyst and may be reduced by further measurement
and variability represents heterogeneity or diversity in a popula-
tion that is irreducible by additional measurements (Spanish-
guidelines proposal). This paper tries to shed light on the need to
separate uncertainty and variability in the EE. METHODS: We
propose the Probabilistic Sensitivity Analysis (PSA) as an efﬁcient
methodology to treat uncertainty associated to the model
“inputs”. In PSA, a single variable (or subset of variables) is
allowed to vary within its speciﬁed probability distribution, and
repeat-run sampling-based simulations are performed to produce
a weighted distribution of output estimates. It is proposed a
bayesian estimation of the results of a target parameter
[q|Data] = [Data|q]*[q]/[Data] subsequently to PSA as an
improvement of the method. We propose calculating the Baye-
sian interval of probability (BIP) [q|a,b] of the costs associated
with treatment during the PSA calculations(it has been assumed
that [q|a,b] ª Beta(a,b)[UNKNOWN NODETYPE 9]), deﬁned as
those that have an interval probability “high” to contain the
parameter; equivalent to frequentist conﬁdence interval
P(qmin  q  qmax) = 1 - a[UNKNOWN NODETYPE 9],
using Markov Chains Monte-Carlo but measured as a probabil-
ity not as conﬁdence (a based). RESULTS: We have studied
different scripts using WinBugs and FirstBayes packages for cal-
culating of the estimated costs BIP in a PSA, simulating highly
skewed distributions of costs. The separation of uncertainty and
variability can affect the study results and policy-making deci-
sions in a non-negligible manner and the best methodology to
treat the uncertainty is PSA. CONCLUSIONS: Furthermore this
paper is a brief introduction to the decision models, their relation
to Bayesian decision theory, and the tools typically used to
describe the uncertainties involved presenting an improvement in
the PSA using a BIP of the estimated parameters as a robust
method.
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Decision-making about resource allocation for guideline imple-
mentation to change clinical practice is inevitably undertaken in
a context of uncertainty surrounding the cost-effectiveness of
both clinical guidelines and implementation strategies. Recently,
a model has been developed in which monetary values are
assigned to health outcomes and economic evidence on guide-
lines and strategies is combined with information on clinical
practice to determine the scope of cost-effective guideline imple-
mentation. Adopting a net beneﬁt approach, the model over-
comes problems with the use of combined ratio statistics when
analyzing decision uncertainty concerning clinical practice
change. OBJECTIVES: The stochastic application of the model is
demonstrated for informing decision-making about the adoption
of an audit and feedback strategy for implementing a guideline
recommending intensive blood glucose control in type 2 diabetes
in primary care in The Netherlands. METHODS: An integrated
Bayesian approach to decision modelling and evidence synthesis
is adopted using Markov Chain Monte Carlo simulation in
WinBUGs. Data on model parameters is gathered from various
sources, with the effectiveness of audit and feedback being
estimated using a pooled, random effects meta-analysis model.
Decision uncertainty is illustrated using cost-effectiveness accept-
ability curves (CEACs) and frontier (CEAF). RESULTS: Deci-
sions about whether to adopt the guidance on blood glucose
control and whether to adopt audit and feedback for its imple-
mentation alter over the range of maximum values that decision-
makers are willing to pay for health gain. Through
simultaneously incorporating uncertain economic evidence on
both guidance and implementation strategy, the CEACs and
CEAF show an increase in decision uncertainty concerning guide-
line implementation. CONCLUSIONS: The stochastic applica-
tion in diabetes care demonstrates that the model provides a
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